Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20210130050179N5
IRCT20210130050179N5
Recruiting
Phase 2

Clinical investigation of the safety and effectiveness of Topaz hair strengthening solution in preventing and improving male pattern androgenic hair loss

Qeshm Rojin Company0 sites20 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHair loss.Nonscarring hair loss, unspecifiedL65.9

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Hair loss.
Sponsor
Qeshm Rojin Company
Enrollment
20
Status
Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Qeshm Rojin Company

Eligibility Criteria

Inclusion Criteria

  • •Male aged 18\-50 years
  • •General health
  • •Hair Loss Status II, III, IV Based on Norwood Scale
  • •Voluntary participation and signing written informed consent

Exclusion Criteria

  • •Chronic active scalp disease other than hair loss
  • •Using any prescribed drug or OTC for hair loss within the past 3 months
  • •Documented sensitivity to formulation components
  • •Any severe weight loss or strict diet therapy during the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Clinical investigation of the safety and effectiveness of Excilia Hair strengthening and ani hair loss Lotion in improving hair lossHair loss.Nonscarring hair loss, unspecifiedL65.9
IRCT20210130050179N6Zist orchid pharmed Company25
Completed
Not Applicable
A clinical study of the Safety and effectiveness of Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) treatment for the palliation of painful bone metastases
JPRN-UMIN000012441Department of Orthopaedic Surgery, Kochi Medical School, Kochi University25
Active, not recruiting
Phase 1
Clinical study to evaluate the efficacity and safety of octagam®10% in idiopathic thrombocytopenic purpura in adults - N/A
EUCTR2005-003552-35-FROctapharma AG116
Completed
Not Applicable
Clinical study for the safety and effectiveness of the use of Perfectha® Derm lidocaine in the treatment of medium wrinkles
ISRCTN20356582Sinclair Pharma70
Not yet recruiting
Not Applicable
Clinical research of the effect and the safety with 0.1% bromfenac sodium hydrate ophthalmic solution and 0.1% betamethasone sodium phosphate ophthalmic, otic and nasal solution in patients with diabetic macular edema
JPRN-UMIN000026201Diabetes Center Tokyo Womens Medical University School of Medicine20